Revvity shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates.

-1.38%

Revvity, Inc. Common Stock

RVTY

0.00

Revvity shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Pre-Bell Movers | MSPR Boosts by 161.1%; Here Are 20 Stocks Moving Premarket

US Market Preview | MSPR Surges 161.4%; IREN Jumps 20% on $9.7B AI Deal With Microsoft; Morgan Stanley Boosts Oil Forecast Amid OPEC+ Pause

How Revvity's (RVTY) Share Buyback and Upgraded EPS Guidance May Shape Investor Expectations

Waters Q3 Adj. EPS $3.40 Beats $3.20 Estimate, Sales $799.887M Beat $781.022M Estimate

Waters Sees Q4 GAAP EPS $4.10-$4.20 vs $4.45 Est

Bioventus Affirms FY2025 Adj EPS Guidance of $0.64-$0.68 vs $0.64 Est; Affirms FY2025 Sales Guidance of $560.000M-$570.000M vs $566.733M Est

Coya Therapeutics Reports Results Of In Vivo Animal Study Designed To Evaluate Effects Of COYA 303 In Well-Characterized In Vivo LPS Preclinical Mouse Model Of Systemic And Neurologic Inflammation

Qiagen Sees Q4 Adj EPS $0.60 vs $0.61 Est